Rekah Pharmaceutical (Israel) Today
| REKA Stock | ILA 1,392 9.00 0.64% |
Performance0 of 100
| Odds Of DistressLess than 9
|
Rekah Pharmaceutical is trading at 1392.00 as of the 11th of December 2024, a 0.64 percent decrease since the beginning of the trading day. The stock's open price was 1401.0. Rekah Pharmaceutical has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 12th of September 2024 and ending today, the 11th of December 2024. Click here to learn more.
Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of prescription and OTC drugs, dermo-cosmetics, vitamins, and nutritional supplements in Israel. The company was founded in 1941 and is based in Holon, Israel. The company has 11.41 M outstanding shares. More on Rekah Pharmaceutical Industry
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Rekah Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Rekah Pharmaceutical's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Rekah Pharmaceutical or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) |
Rekah Pharmaceutical Industry (REKA) is traded on Tel Aviv Stock Exchange in Israel and employs 399 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 193.93 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Rekah Pharmaceutical's market, we take the total number of its shares issued and multiply it by Rekah Pharmaceutical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Rekah Pharmaceutical operates under Pharmaceuticals sector and is part of Health Care industry. The entity has 11.41 M outstanding shares.
Rekah Pharmaceutical Industry has accumulated about 31.61 M in cash with 21.17 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.77.
Check Rekah Pharmaceutical Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Rekah Pharmaceutical is 193.93 Million. Rekah Pharmaceutical has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Note, that even with substantial debt, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company at some point.
Check Rekah Ownership Details
Rekah Pharmaceutical Risk Profiles
Although Rekah Pharmaceutical's alpha and beta are two of the key measurements used to evaluate Rekah Pharmaceutical's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.64 | |||
| Semi Deviation | 3.51 | |||
| Standard Deviation | 3.59 | |||
| Variance | 12.86 |
Rekah Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Rekah Pharmaceutical without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Top Crypto Exchanges Now
Top Crypto ExchangesSearch and analyze digital assets across top global cryptocurrency exchanges |
| All Next | Launch Module |
Rekah Pharmaceutical Corporate Management
Elected by the shareholders, the Rekah Pharmaceutical's board of directors comprises two types of representatives: Rekah Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rekah. The board's role is to monitor Rekah Pharmaceutical's management team and ensure that shareholders' interests are well served. Rekah Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rekah Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yuval Elgrabli | Deputy Devel | Profile | |
| Yuval CPA | Chief Officer | Profile | |
| Jacob Elgrably | Chief Shalpharm | Profile | |
| Chaim Cohen | Chief Officer | Profile | |
| Jack Azran | Chief Technologies | Profile | |
| Yaakov Elgrabli | Chief Ltd | Profile | |
| Georgette Elgrabli | Director Director | Profile |
Other Information on Investing in Rekah Stock
Rekah Pharmaceutical financial ratios help investors to determine whether Rekah Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Rekah with respect to the benefits of owning Rekah Pharmaceutical security.